Stoltmann Law Offices Continues to Investigate UBS Puerto

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stoltmann Law Offices Continues to Investigate UBS Puerto Rico for Investment Losses in UBS Puerto Rico Related Bond Funds

CHICAGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Stoltmann Law Offices announces its continued investigation into UBS Puerto Rico for sales practices related to its leveraged closed end bond funds. Many investors in the closed end and open end Puerto Rico related bond funds may have an actionable claim against UBS for multiple causes of action, including fraud, unsuitable investment recommendations and other related actions.

According to Chicago securities attorney Andrew Stoltmann, "Brokerage firms have the duty to make suitable, appropriate recommendations to clients. In addition, firms cannot misstate the risks or omit material, important risks associated with an investment. Failure to do so can make the firm responsible for the losses the client sustains.

According to Stoltmann, "We believe many conservative or elderly clients in Puerto Rico were sold UBS proprietary closed end and open end investments without having been told the full risks associated with the products, including the utilization of leverage. In some cases, the true risks of these investments were not disclosed to the clients. Many investors couldn't afford to take the risks associated with these investments. For clients who invested in the following funds, some, or all, of the investment losses might be recoverable through the FINRA arbitration process or through lawsuits, or class action lawsuits: Tax-Free Puerto Rico Fund, Tax-Free Puerto Rico Fund II, Tax-Free Puerto Rico Target Maturity Fund, Puerto Rico AAA Portfolio Target Maturity Fund, Inc., Puerto Rico AAA Portfolio Bond Fund, Puerto Rico AAA Portfolio Bond Fund II, Puerto Rico GNMA & U.S. Government Target Maturity Fund, Puerto Rico Mortgage-Backed & U.S. Government Securities Fund, Puerto Rico Fixed Income Fund, Puerto Rico Fixed Income Fund II, Puerto Rico Fixed Income Fund III, Puerto Rico Fixed Income Fund IV, Puerto Rico Fixed Income Fund V, Puerto Rico Fixed Income Fund VI, Puerto Rico Short Term Investment Fund, Multi-Select Securities Puerto Rico Fund, UBS IRA Select Growth & Income Puerto Rico Fund, Puerto Rico Investors Family of Funds, Puerto Rico Investors Tax-Free Fund, Puerto Rico Investors Tax-Free Fund II, Puerto Rico Investors Tax-Free Fund III, Puerto Rico Investors Tax-Free Fund IV, Puerto Rico Investors Tax-Free Fund V, Puerto Rico Investors Tax-Free Fund VI, Puerto Rico Tax-Free Target Maturity Fund, Puerto Rico Tax-Free Target Maturity Fund II, Inc., Puerto Rico Investors Bond Fund I."

Stoltmann also disclosed: "UBS financial advisors are not our targets and we will not be naming them in any FINRA arbitration claims. Our exclusive target is UBS."

For more information on recovering investment losses on a contingency fee basis, please visit www.InvestmentFraud.Pro .

Stoltmann Law Offices Andrew Stoltmann o: 312-332-4200 c: 312-545-5711 10 S. LaSalle 35th Floor Chicago, IL 60603

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Century Communities Expands Home Offerings in Nashville Region

Updated Category News Views 173

Century Communities Expands Home Offerings in Nashville Region Century Communities, Inc.—a prominent national homebuilder known for its innovative approaches in home sales—is excited to announce a significant expansion of its housing offerings in the Nashville area. This growth is indicative of Century’s commitment to meet the increasing demand for quality living...

Continue Reading
Wahl Professional Unveils New KM Series Grooming Clippers

Updated Category News Views 182

Wahl Professional Unveils New KM Series Grooming Clippers Wahl Professional, a leader in the grooming industry, is proud to announce the introduction of two exciting new models in their KM Series tailored for animal grooming. These innovative clippers aim to enhance the grooming experience for professionals and pet owners by simplifying coat maintenance with improved...

Continue Reading
The Reality of Earning as a Veteran at Lockheed Martin

Updated Category News Views 167

A Veteran's Journey in the Defense Industry A skilled defense worker's financial snapshot reveals both the lucrative reality of America's military-industrial complex and the lasting toll of service that no amount of compensation can truly repair. Behind the Numbers: Insights from a Defense Worker The numbers tell one story: A veteran working for Lockheed Martin (NYSE:LMT)...

Continue Reading
Viasat Leader to Speak at Deutsche Bank Space Summit

Updated Category News Views 123

Viasat Announces Key Participation in Global Space Summit Viasat, Inc. (NASDAQ: VSAT), renowned for its leadership in satellite communications, is set to engage in significant discussions at the Deutsche Bank Global Space Summit. The event will feature prominent figures from both commercial and governmental sectors. Viasat's President of Global Space Networks, Craig...

Continue Reading
Rachel Reeves Aims to Revitalize UK Economy with Budget Plan

Updated Category News Views 208

Overview of the Economic Reset British finance minister Rachel Reeves is making significant strides as she approaches her upcoming budget announcement. With this budget, Reeves is looking to smoothly transition the country toward a more favorable economic environment. This initiative is crucial as the Labour Party prepares to take the reins after a long absence from...

Continue Reading